Skip to main content
Figure 4 | Molecular Cancer

Figure 4

From: In non-transplant patients with multiple myeloma, the pre-treatment level of clonotypic cells predicts event-free survival

Figure 4

Remission VDJ% and relative reduction of remission BM samples. The post treatment VDJ% from a front-line trial of relapsed MM patients, comparing standard VAD to bortezomib just prior to ASCT (A). The times reduction of the VDJ% in the same samples are plotted in B. In relapsed patients, the VDJ% is noted in C after having been treated with dexamethasone, lenalidomide or bortezomib. The line through each column represents the mean. Dex=dexamethasone.

Back to article page

Molecular Cancer

ISSN: 1476-4598